Department of Neurology and Suzhou Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Interv Neuroradiol. 2022 Feb;28(1):104-114. doi: 10.1177/15910199211016258. Epub 2021 May 14.
We compared outcomes and adverse events of thrombectomy versus medical management in acute ischemic stroke (AIS) patients with baseline large infarct core.
We searched Ovid MEDLINE(R) ALL, Cochrane Library Clinical Controlled Trials and EMBASE from inception to January 2021 for studies comparing thrombectomy and medical management alone in AIS patients who had ASPECTS <=7 or ischemic core volume >=50 ml. Imaging modalities to valuate ASPECTS and core volume were without restriction. The functional outcome was measured by mRS (modified Rankin Scale) score 0-2 at 90 days or discharge. The safety end point included the rates of mortality and sICH (symptomatic intracranial hemorrhage) or PH2 (parenchymal hematoma type 2).
Fourteen studies with a total of 2547 patients (thrombectomy n = [1197]; medical care alone [n = 1350]) fulfilled our criteria. As for patients with low ASPECTS, pooled results indicated a higher odds of good functional outcome (OR = 3.47; 95% CI 1.99 to 6.07; P < 0.0001, I=66%) and a lower risk of mortality (OR = 0.62; 95% CI 0.46 to 0.83; P = 0.001, I=32%) in thrombectomy group compared with no thrombectomy group, but the risk of sICH or PH2 did not differ between two groups. As for patients with large core volume, both functional outcome and safety end point between two groups showed no statistically significant difference.
Thrombectomy remained safe and effective by careful selection in patients with low ASPECTS. More studies were warranted to explore contraindications for mechanical thrombectomy in AIS patients, especially in patients with large core volume.
我们比较了基线大梗死核心的急性缺血性脑卒中(AIS)患者接受血栓切除术与药物治疗的结局和不良事件。
我们在 Ovid MEDLINE(R)ALL、Cochrane 图书馆临床试验和 EMBASE 中检索了从成立到 2021 年 1 月的研究,这些研究比较了 ASPECTS <=7 或缺血核心体积 >=50ml 的 AIS 患者单独接受血栓切除术与药物治疗的情况。评估 ASPECTS 和核心体积的成像方式不受限制。功能结局通过 90 天或出院时的 mRS(改良 Rankin 量表)评分 0-2 来衡量。安全性终点包括死亡率和 sICH(症状性颅内出血)或 PH2(实质血肿类型 2)的发生率。
四项研究共纳入 2547 例患者(血栓切除术 n=1197;药物治疗单独 n=1350)符合我们的标准。对于 ASPECTS 较低的患者,汇总结果表明血栓切除术组获得良好功能结局的可能性更高(OR=3.47;95%CI 1.99 至 6.07;P<0.0001,I=66%),死亡率较低(OR=0.62;95%CI 0.46 至 0.83;P=0.001,I=32%),但两组 sICH 或 PH2 的风险无差异。对于核心体积较大的患者,两组的功能结局和安全性终点均无统计学差异。
对于 ASPECTS 较低的患者,通过仔细选择,血栓切除术仍然是安全有效的。需要更多的研究来探讨机械血栓切除术在 AIS 患者中的禁忌证,特别是在核心体积较大的患者中。